Unity Biotechnology said Monday that its experimental treatment for osteoarthritis failed to improve knee pain compared to a placebo in a mid-stage clinical trial.
The outcome is likely to raise new doubts about the biotech’s ability to develop drugs to reverse the symptoms and diseases associated with aging.
Unity shares fell 55% to $5.65 in early trading. The company went public in 2018 at $17 per share.
About the Author Reprints
